Concomitant interleukin-2-doxorubicin (ADR) schedule in patients (PTS) with advanced soft tissue sarcomas (ASTS): A pharmacokinetic study

被引：0
|
作者：
LeCesne, A [1 ]
Vassal, G [1 ]
Farace, F [1 ]
Spielmann, M [1 ]
LeChevalier, T [1 ]
Tursz, T [1 ]
Escudier, B [1 ]
机构：
[1] INST GUSTAVE ROUSSY,F-94805 VILLEJUIF,FRANCE
来源：
EUROPEAN JOURNAL OF CANCER | 1995年 / 31A卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：586 / 586
页数：1
相关论文
共 50 条
  • [31] Growth modulation index and RECIST-based STBSG-EORTC criteria for the assessment of drug activity in advanced soft tissue sarcoma (ASTS) patients (pts)
    Cousin, Sophie
    Blay, Jean-Yves
    Bertucci, Francois
    Isambert, Nicolas
    Italiano, Antoine
    Bompas, Emmanuelle
    Ray-Coquard, Isabelle
    Perrot, Delphine
    Binh Bui Nguyen
    Chaix, Marie
    Chaigneau, Loic
    Corradini, Nadege
    Penel, Nicolas
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] Phase II study of eribulin mesylate in patients (pts) with advanced soft tissue sarcoma (STS).
    Naito, Yoichi
    Kawai, Akira
    Araki, Nobuhito
    Ozaki, Toshifumi
    Sugiura, Hideshi
    Yazawa, Yasuo
    Morioka, Hideo
    Matsumine, Akihiko
    Hiraiwa, Masahide
    Asami, Shun
    Isu, Kazuo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] Activity of doxorubicin after high-dose ifosfamide in adult patients with advanced soft tissue sarcoma: A study of the Spanish Group for Research on Sarcomas (GEIS)
    Buesa, JM
    Fra, J
    Anton, A
    Lopez-Pousa, A
    Martin, J
    del Muro, JG
    Escudero, P
    Casado, A
    Poveda, A
    ANNALS OF ONCOLOGY, 1998, 9 (07) : 783 - 785
  • [34] Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: Multicenter phase II and pharmacokinetic study
    Garcia-Carbonero, R
    Supko, JG
    Maki, RG
    Manola, J
    Ryan, DP
    Harmon, D
    Puchalski, TA
    Goss, G
    Seiden, MV
    Waxman, A
    Quigley, MT
    Lopez, T
    Sancho, MA
    Limeno, J
    Guzman, C
    Demetri, GD
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) : 5484 - 5492
  • [35] A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma - A study by the Spanish group for research on sarcomas
    del Muro, XG
    Lopez-Pousa, A
    Martin, J
    Buesa, JM
    Martinez-Trufero, J
    Casado, A
    Poveda, A
    Cruz, J
    Bover, I
    Maurel, J
    CANCER, 2005, 104 (08) : 1706 - 1712
  • [36] Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas
    Heymach, JV
    Desai, J
    Manola, J
    Davis, DW
    McConkey, DJ
    Harmon, D
    Ryan, DP
    Goss, G
    Quigley, T
    Van den Abbeele, AD
    Silverman, SG
    Connors, S
    Folkman, J
    Fletcher, CDM
    Demetri, GD
    CLINICAL CANCER RESEARCH, 2004, 10 (17) : 5732 - 5740
  • [37] Phase II Trial of Topotecan by Continuous Infusion in Patients with Advanced Soft Tissue Sarcomas, a SWOG Study
    G. Thomas Budd
    Cathryn Rankin
    Laura F. Hutchins
    Lucas Wong
    Paul J. Petruska
    Karen Antman
    Investigational New Drugs, 2002, 20 : 129 - 132
  • [38] Phase II trial of topotecan by continuous infusion in patients with advanced soft tissue sarcomas, a SWOG study
    Budd, GT
    Rankin, C
    Hutchins, LF
    Wong, L
    Petruska, PJ
    Antman, K
    INVESTIGATIONAL NEW DRUGS, 2002, 20 (01) : 129 - 132
  • [39] High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group
    Nielsen, OS
    Dombernowsky, P
    Mouridsen, H
    Crowther, D
    Verweij, J
    Buesa, J
    Steward, W
    Daugaard, S
    van Glabbeke, M
    Kirkpatrick, A
    Tursz, T
    BRITISH JOURNAL OF CANCER, 1998, 78 (12) : 1634 - 1639
  • [40] High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group
    OS Nielsen
    P Dombernowsky
    H Mouridsen
    D Crowther
    J Verweij
    J Buesa
    W Steward
    S Daugaard
    M van Glabbeke
    A Kirkpatrick
    T Tursz
    British Journal of Cancer, 1998, 78 : 1634 - 1639
12345